Letters Section Editor: Jody W. Zylke, MD, Senior Editor.
Author Affiliation: George Washington University, Washington, DC (email@example.com).
To the Editor: Dr Hatzis and colleagues1 reported the creation of a genomic predictor that identifies patients with a high probability of survival following taxane-anthracycline chemotherapy for invasive breast cancer. Two issues require clarification.
First, how were the patients recruited for this study? What were the inclusion and exclusion criteria? How were patients selected for the taxane-anthracycline chemotherapy? Did the patients receive any neoadjuvant or other adjuvant therapy? Were the patients enrolled consecutively?
Burke HB. Genomic Predictor of Survival After Chemotherapy for Breast Cancer. JAMA. 2011;306(7):707-709. doi:10.1001/jama.2011.1148